<?xml version="1.0" encoding="UTF-8"?>
<p id="par0230">Lopinavir combined with ribavirin also presents a synergistic effect being able to inhibit the cytopathic effect of SARS-CoV 
 <italic>in vivo</italic> and reduce the death rate by about 20%â€“30% on 
 <italic>in vitro</italic> and 
 <italic>in vivo</italic> experiments [
 <xref rid="bib0575" ref-type="bibr">[115]</xref>, 
 <xref rid="bib0580" ref-type="bibr">[116]</xref>, 
 <xref rid="bib0585" ref-type="bibr">[117]</xref>]. A molecular modeling study for SARS-CoV-2 was recently carried out to assess the binding effect between Lopinavir, Ritonavir, and two viral proteases, CEP_C30 and PLVL. This study showed that these anti-HIV drugs can bind and induce changes in conformations mainly in CEP_C30 [
 <xref rid="bib0590" ref-type="bibr">118</xref>]. Even with the promising results to MERS-CoV and SARS-CoV, the use of high doses of ribavirin is worrying, since it can trigger side effects such as anemia [
 <xref rid="bib0595" ref-type="bibr">119</xref>].
</p>
